3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Urinary Bladder Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Medulloblastoma
1
Lung Neoplasms
1
Leukemia, Hairy Cell
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Ependymoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma in Situ
1
Breast Neoplasms
1
Interventions
Paclitaxel
42
Carboplatin
37
Bevacizumab
29
liposomal doxorubicin
20
Taxes
18
Specimen Handling
18
pembrolizumab
16
olaparib
16
Magnetic Resonance Spectroscopy
16
Gemcitabine
16
Topotecan
13
Immunoglobulin G
12
Disulfides
12
Biopsy
11
niraparib
8
mirvetuximab soravtansine
8
Nivolumab
7
Doxorubicin
7
Cyclophosphamide
6
Cisplatin
6
Drug Therapy
5
130-nm albumin-bound paclitaxel
5
cemiplimab
4
cediranib
4
Letrozole
4
Injections
4
Docetaxel
4
1-dodecylpyridoxal
4
sarilumab
3
rucaparib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fallopian Tube Neoplasms
×
Histamine Antagonists
×
1 year
×
Clear all
NCT06824467
2026-05-29
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3
Recruiting
770 enrolled